Corcept Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Corcept Therapeutics hat ein Gesamteigenkapital von $547.9M und eine Gesamtverschuldung von $0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $655.9M bzw. $108.1M. Corcept Therapeutics Das EBIT des Unternehmens beträgt $121.9M, so dass der Zinsdeckungsgrad -6.4 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $410.8M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	-6.4x
Bargeld	US$410.76m
Eigenkapital	US$547.86m
Gesamtverbindlichkeiten	US$108.07m
Gesamtvermögen	US$655.94m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11

I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease

Jun 09

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: CORTDie kurzfristigen Aktiva des Unternehmens ($503.4M) übersteigen seine kurzfristigen Passiva ($97.2M).

Langfristige Verbindlichkeiten: CORTDie kurzfristigen Vermögenswerte des Unternehmens ($503.4M) übersteigen seine langfristigen Verbindlichkeiten ($10.9M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: CORT ist schuldenfrei.

Schulden abbauen: CORT hatte vor 5 Jahren keine Schulden.

Schuldendeckung: CORT hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.

Zinsdeckung: CORT hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

Corcept Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

Price target increased by 14% to US$49.70

Chief Development Officer notifies of intention to sell stock

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 Grace Trial of Relacorilant in Patients with Hypercortisolism (Cushing’S Syndrome)

President of Endocrinology notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial

Corcept Therapeutics Incorporated to Report Q1, 2024 Results on May 01, 2024

Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

New minor risk - Shareholder dilution

Corcept Therapeutics Incorporated, Annual General Meeting, May 17, 2024

Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

Chief Accounting Officer notifies of intention to sell stock

Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome

President of Endocrinology notifies of intention to sell stock

President of Endocrinology exercised options and sold US$364k worth of stock

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

President of Endocrinology notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial

Corcept Therapeutics Incorporated to Report Q4, 2023 Results on Feb 15, 2024

Price target increased by 11% to US$39.60

New minor risk - Share price stability

Corcept Therapeutics Incorporated Appoints Roberto Vieira as President, Oncology

Chief Scientific Officer exercised options and sold US$728k worth of stock

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024

Chief Development Officer notifies of intention to sell stock

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

President of Corcept Endocrinology notifies of intention to sell stock

Consensus EPS estimates increase by 13%

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Price target increased by 8.1% to US$36.83

President of Corcept Endocrinology notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Appoints Monica Tellado as President, Emerging Markets

Corcept Therapeutics Incorporated Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis

Corcept Therapeutics Incorporated to Report Q3, 2023 Results on Nov 01, 2023

President of Corcept Endocrinology exercised options and sold US$452k worth of stock

President of Corcept Endocrinology notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

President of Corcept Endocrinology notifies of intention to sell stock

Chief Scientific Officer recently sold US$632k worth of stock

Chief Scientific Officer exercised options and sold US$811k worth of stock

Investor sentiment improves as stock rises 22%

Price target increased by 7.3% to US$32.92

Corcept Therapeutics Incorporated to Report Q2, 2023 Results on Aug 02, 2023

Corcept Therapeutics Incorporated Publishes Results of Corcept’S Phase 2 Trial of Relacorilant in Women with Platinum-Resistant Ovarian Cancer

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Chief Accounting Officer notifies of intention to sell stock

Chief Business Officer & Secretary recently sold US$1.1m worth of stock

Chief Business Officer & Secretary exercised options and sold US$1.3m worth of stock

Consensus EPS estimates fall by 21%, revenue upgraded

First quarter 2023 earnings: EPS misses analyst expectations

Corcept Therapeutics Incorporated Revises Revenue Guidance for 2023

Insufficient new directors

Consensus EPS estimates fall by 21%

Full year 2022 earnings: EPS misses analyst expectations

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Price target decreased by 7.6% to US$31.60

Corcept Therapeutics Incorporated to Report Q4, 2022 Results on Feb 28, 2023

Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Corcept Therapeutics Provides Miricorilant Clinical Development Update

Price target increased to US$35.00

Chief Business Officer & Secretary recently sold US$615k worth of stock

President of Corcept Endocrinology exercised options and sold US$557k worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2022

Corcept Therapeutics Incorporated to Report Q3, 2022 Results on Nov 03, 2022

Corcept Therapeutics Incorporated Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis

Corcept Therapeutics starts phase 2 trial of its ALS treatment

Chief Scientific Officer exercised options and sold US$719k worth of stock

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Corcept extends distribution agreement for Cushing’s syndrome drug